Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer
The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Standard chemotherapy is associated with low response rates and short progression-free survival among patients with pretreated metastatic triple-negative breast cancer. Sacituzumab govitecan-hziy is an antibody-drug conjugate that combines a humanized monoclonal antibody, which targets the human trophoblast cell-surface antigen 2 (Trop-2), with SN-38, which is conjugated to the antibody by a cleavable linker. Sacituzumab govitecan-hziy enables delivery of high concentrations of SN-38 to tumors. METHODS: We conducted a phase 1/2 single-group, multicenter trial involving patients with advanced epithelial cancers who received sacituzumab govitecan-hziy intravenously on days 1 and 8 of each 21-day cycle until disease progression or unacceptable toxic effects. A total of 108 patients received sacituzumab govitecan-hziy at a dose of 10 mg per kilogram of body weight after receiving at least two previous anticancer therapies for metastatic triple-negative breast cancer. The end points included safety; the objective response rate (according to Response Evaluation Criteria in Solid Tumors, version 1.1), which was assessed locally; the duration of response; the clinical benefit rate (defined as a complete or partial response or stable disease for at least 6 months); progression-free survival; and overall survival. Post hoc analyses determined the response rate and duration, which were assessed by blinded independent central review. RESULTS: The 108 patients with triple-negative breast cancer had received a median of 3 previous therapies (range, 2 to 10). Four deaths occurred during treatment; 3 patients (2.8%) discontinued treatment because of adverse events. Grade 3 or 4 adverse events (in ≥10% of the patients) included anemia and neutropenia; 10 patients (9.3%) had febrile neutropenia. The response rate (3 complete and 33 partial responses) was 33.3% (95% confidence interval [CI], 24.6 to 43.1), and the median duration of response was 7.7 months (95% CI, 4.9 to 10.8); as assessed by independent central review, these values were 34.3% and 9.1 months, respectively. The clinical benefit rate was 45.4%. Median progression-free survival was 5.5 months (95% CI, 4.1 to 6.3), and overall survival was 13.0 months (95% CI, 11.2 to 13.7). CONCLUSIONS: Sacituzumab govitecan-hziy was associated with durable objective responses in patients with heavily pretreated metastatic triple-negative breast cancer. Myelotoxic effects were the main adverse reactions. (Funded by Immunomedics; IMMU-132-01 ClinicalTrials.gov number, NCT01631552.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The overall response rate was 33.3% (95% CI 24.6-43.1), with a median duration of response of 7.7 months (95% CI 4.9-10.8).”
From 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5) (2020) · cites this paper as [72]
In the citing paper
“Of the patients with a response to sacituzumab govitecan-hziy, 55.6% maintained their response for ≥6 months and 16.7% maintained their response for ≥12 months.”
From 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5) (2020) · cites this paper as [72]
Citations
Cites
Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer
Schmid, P., Adams, S., Rugo, H. S., Schneeweiss, A., Barrios, C. H., Iwata, H., Diéras, V., Hegg, R., Im, S.-A., Shaw Wright, G., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1809615 · Cited by 4,350
Self-citationTrastuzumab emtansine for HER2-positive advanced breast cancer
Verma, S., Miles, D., Gianni, L., Krop, I. E., Welslau, M., Baselga, J., Pegram, M., Oh, D.-Y., Diéras, V., Guardino, E., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1209124 · Cited by 3,834
Palbociclib and letrozole in advanced breast cancer
Finn, R. S., Martin, M., Rugo, H. S., Jones, S., Im, S.-A., Gelmon, K., Harbeck, N., Lipatov, O. N., Walshe, J. M., Moulder, S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607303 · Cited by 3,007
Self-citationCombined BRAF and MEK inhibition in melanoma with BRAF V600 mutations
Flaherty, K. T., Infante, J. R., Daud, A., Gonzalez, R., Kefford, R. F., Sosman, J., Hamid, O., Schuchter, L., Cebon, J., Ibrahim, N., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1210093 · Cited by 2,810
Crizotinib in ROS1-Rearranged Non–Small-Cell Lung Cancer
Shaw, A. T., Ou, S.-H. I., Bang, Y.-J., Camidge, D. R., Solomon, B. J., Salgia, R., Riely, G. J., Varella-Garcia, M., Shapiro, G. I., Costa, D. B., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1406766 · Cited by 1,964
Breast cancer statistics, 2015: Convergence of incidence rates between black and white women
DeSantis, C. E., Fedewa, S. A., Goding Sauer, A., Kramer, J. L., Smith, R. A., & Jemal, A. (2016) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21320 · Cited by 1,252
Cortes, J., O'Shaughnessy, J., Loesch, D., Blum, J. L., Vahdat, L. T., Petrakova, K., Chollet, P., Manikas, A., Diéras, V., Delozier, T., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60070-6 · Cited by 1,094
Self-citationKohler, B. A., Sherman, R. L., Howlader, N., Jemal, A., Ryerson, A. B., Henry, K. A., Boscoe, F. P., Cronin, K. A., Lake, A., Noone, A.-M., et al. (2015) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djv048 · Cited by 915
Kawato, Y., Aonuma, M., Hirota, Y., Kuga, H., & Sato, K. (1991) · PubMed · Cited by 865
Goldenberg, D. M., Cardillo, T. M., Govindan, S. V., Rossi, E. A., & Sharkey, R. M. (2015) · Oncotarget · doi:10.18632/oncotarget.4318 · Cited by 495
Self-citation
Research works printed but not linked: 1
- 10.1002/(SICI)1097-0215(19980529)76:5<671::AID-IJC10>3.0.CO;2-7 · DOI · Paper page
Cited by
Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer
Bardia, A., Hurvitz, S. A., Tolaney, S. M., Loirat, D., Punie, K., Oliveira, M., Brufsky, A., Sardesai, S. D., Kalinsky, K., Zelnak, A. B., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2028485 · Cited by 1,711
“of patients (%) 54 (23) 89 (38) 65 (24) 100 (38)”
Self-citationLoibl, S., Poortmans, P., Morrow, M., Denkert, C., & Curigliano, G. (2021) · The Lancet · doi:10.1016/s0140-6736(20)32381-3 · Cited by 1,648
Treatment landscape of triple-negative breast cancer — expanded options, evolving needs
Bianchini, G., De Angelis, C., Licata, L., & Gianni, L. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00565-2 · Cited by 1,382
5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5)
Cardoso, F., Paluch-Shimon, S., Senkus, E., Curigliano, G., Aapro, M. S., André, F., Barrios, C. H., Bergh, J., Bhattacharyya, G. S., Biganzoli, L., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.09.010 · Cited by 1,369
“Sacituzumab govitecan-hziy has demonstrated promising activity in advanced lines for triple-negative ABC in a phase I/II study of 108 patients who had received a range of 2-10 prior treatments for metastatic disease.(72) The overall response rate was 33.”
BackgroundSelf-citationUnlocking the potential of antibody–drug conjugates for cancer therapy
Drago, J. Z., Modi, S., & Chandarlapaty, S. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00470-8 · Cited by 1,150
Recent advances in therapeutic strategies for triple-negative breast cancer
Li, Y., Zhang, H., Merkher, Y., Chen, L., Liu, N., Leonov, S., & Chen, Y. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01341-0 · Cited by 956
“IMMU-132 could release both extracellular and intracellular SN-38.”
MethodInfluentialBurstein, H. J., Curigliano, G., Loibl, S., Dubsky, P., Gnant, M., Poortmans, P., Colleoni, M., Denkert, C., Piccart-Gebhart, M., Regan, M., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz235 · Cited by 667
“Chemotherapy for triple-negative breast cancers Chemotherapy is the mainstay of neo/adjuvant treatment of TNBC. Based on a recent meta-analysis [26], the Panel endorsed ‘dose-dense’ treatment as the preferred approach for anthracycline- and taxane-based neo/adjuvant chemotherapy regimens.”
BackgroundInfluentialBreast Cancer—Epidemiology, Classification, Pathogenesis and Treatment (Review of Literature)
Smolarz, B., Nowak, A. Z., & Romanowicz, H. (2022) · Cancers · doi:10.3390/cancers14102569 · Cited by 587
Banerji, U., van Herpen, C. M. L., Saura, C., Thistlethwaite, F., Lord, S., Moreno, V., Macpherson, I. R., Boni, V., Rolfo, C., de Vries, E. G. E., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30328-6 · Cited by 547
Tagawa, S. T., Balar, A. V., Petrylak, D. P., Kalebasty, A. R., Loriot, Y., Fléchon, A., Jain, R. K., Agarwal, N., Bupathi, M., Barthelemy, P., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.20.03489 · Cited by 543
“The safety results reported here are also consistent with previous reports in other cancers.(28,30,53-55)”
ResultTriple Negative Breast Cancer Treatment Options and Limitations: Future Outlook
Obidiro, O., Battogtokh, G., & Akala, E. O. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15071796 · Cited by 511
“Sacituzumab govitecan (SG) was approved by the FDA in 2016 to manage metastatic triple-negative breast cancer patients who have had at least two previous therapies [120].”
Triple‑negative breast cancer therapy: Current and future perspectives (Review)
Won, K., & Spruck, C. (2020) · International Journal of Oncology · doi:10.3892/ijo.2020.5135 · Cited by 527
“Myelotoxic effects were the main adverse reactions and grade 3 or 4 AEs included anemia and neutropenia (104).”
Breast Cancer Treatments: Updates and New Challenges
Burguin, A., Diorio, C., & Durocher, F. (2021) · Journal of Personalized Medicine · doi:10.3390/jpm11080808 · Cited by 488
ImmunoPET: Concept, Design, and Applications
Wei, W., Rosenkrans, Z. T., Liu, J., Huang, G., Luo, Q.-Y., & Cai, W. (2020) · Chemical Reviews · doi:10.1021/acs.chemrev.9b00738 · Cited by 484
Site-selective modification strategies in antibody–drug conjugates
Walsh, S. J., Bargh, J. D., Dannheim, F. M., Hanby, A. R., Seki, H., Counsell, A. J., Ou, X., Fowler, E., Ashman, N., Takada, Y., et al. (2021) · Chemical Society Reviews · doi:10.1039/d0cs00310g · Cited by 461
Emerging new therapeutic antibody derivatives for cancer treatment
Jin, S., Sun, Y., Liang, X., Gu, X., Ning, J., Xu, Y., Chen, S., & Pan, L. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00868-x · Cited by 459
Park, J. J. H., Siden, E., Zoratti, M. J., Dron, L., Harari, O., Singer, J., Lester, R. T., Thorlund, K., & Mills, E. J. (2019) · Trials · doi:10.1186/s13063-019-3664-1 · Cited by 441
The Landscape of Targeted Therapies in TNBC
Vagia, E., Mahalingam, D., & Cristofanilli, M. (2020) · Cancers · doi:10.3390/cancers12040916 · Cited by 450
Bardia, A., Messersmith, W. A., Kio, E. A., Berlin, J. D., Vahdat, L., Masters, G. A., Moroose, R., Santin, A. D., Kalinsky, K., Picozzi, V., et al. (2021) · Annals of Oncology · doi:10.1016/j.annonc.2021.03.005 · Cited by 400
Self-citationAlmansour, N. M. (2022) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2022.836417 · Cited by 397
“In this case, the active metabolite is irinotecan in conjugation with anti-trophoblast cell-surface antigen 2 antibody (Bardia et al., 2019).”
Antibody–Drug Conjugates for Cancer Therapy
Hafeez, U., Parakh, S., Gan, H. K., & Scott, A. M. (2020) · Molecules · doi:10.3390/molecules25204764 · Cited by 395
“The most common adverse events noted with this ADC are myelosuppression and diarrhoea [97].”
BackgroundOkajima, D., Yasuda, S., Maejima, T., Karibe, T., Sakurai, K., Aida, T., Toki, T., Yamaguchi, J., Kitamura, M., Kamei, R., et al. (2021) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-21-0206 · Cited by 339
Targeting Topoisomerase I in the Era of Precision Medicine
Thomas, A., & Pommier, Y. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-1089 · Cited by 337
“In a phase I/II trial of third-line or higher line of therapy for metastatic triple-negative breast cancer (TNBC), IMMU-132 produced durable objective responses (51).”
BackgroundBardia, A., Tolaney, S. M., Punie, K., Loirat, D., Oliveira, M., Kalinsky, K., Zelnak, A., Aftimos, P., Dalenc, F., Sardesai, S., et al. (2021) · Annals of Oncology · doi:10.1016/j.annonc.2021.06.002 · Cited by 326
Self-citationGupta, G. K., Collier, A. L., Lee, D., Hoefer, R. A., Zheleva, V., Siewertsz van Reesema, L. L., Tang-Tan, A. M., Guye, M. L., Chang, D. Z., Winston, J. S., et al. (2020) · Cancers · doi:10.3390/cancers12092392 · Cited by 331
“In April 2020, Sacituzumab govitecan-hziy (Trodelvy) received accelerated FDA approval for heavily pretreated and advanced mTNBC based on these promising and exciting results [205,206].”
BackgroundAntibody–Drug Conjugates (ADCs): current and future biopharmaceuticals
Wang, R., Hu, B., Pan, Z., Mo, C., Zhao, X., Liu, G., Hou, P., Cui, Q., Xu, Z., Wang, W., et al. (2025) · Journal of Hematology & Oncology · doi:10.1186/s13045-025-01704-3 · Cited by 285
“In contrast to the hydrazone bonds, the CL2 A linker contains a nine-polyethylene glycol structure, which increases the water solubility of SN-38, thus significantly improving sacituzumab govitecan’s serum stability for TNBC [130, 131].”
Marra, A., Trapani, D., Viale, G., Criscitiello, C., & Curigliano, G. (2020) · npj Breast Cancer · doi:10.1038/s41523-020-00197-2 · Cited by 317
Current State of Breast Cancer Diagnosis, Treatment, and Theranostics
Bhushan, A., Gonsalves, A., & Menon, J. U. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13050723 · Cited by 298
Jiang, Y.-Z., Liu, Y., Xiao, Y., Hu, X., Jiang, L., Zuo, W.-J., Ma, D., Ding, J., Zhu, X., Zou, J., et al. (2021) · Cell Research · doi:10.1038/s41422-020-0375-9 · Cited by 298
Sacituzumab Govitecan: First Approval
Syed, Y. Y. (2020) · Drugs · doi:10.1007/s40265-020-01337-5 · Cited by 293
“Among 108 patients with mTNBC receiving sacituzumab govitecan in IMMU-132-01, grade 3 AEs occurred in 66% of patients; the most common (incidence ≥ 5”
BackgroundInfluentialTriple-negative breast cancer therapeutic resistance: Where is the Achilles' heel?
Bai, X., Ni, J., Beretov, J., Graham, P., & Li, Y. (2021) · Cancer Letters · doi:10.1016/j.canlet.2020.10.016 · Cited by 283
Coates, J. T., Sun, S., Leshchiner, I., Thimmiah, N., Martin, E. E., McLoughlin, D., Danysh, B. P., Slowik, K., Jacobs, R. A., Rhrissorrakrai, K., et al. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-0702 · Cited by 248
“In a phase I/II clinical trial, patients with metastatic TNBC (median of 3 prior regimens) treated with SG had remarkable therapeutic responses (33%), including complete responses (7).”
Self-citationAntibody–drug conjugates in solid tumors: a look into novel targets
Criscitiello, C., Morganti, S., & Curigliano, G. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01035-z · Cited by 250
Peptide–Drug Conjugates with Different Linkers for Cancer Therapy
Alas, M., Saghaeidehkordi, A., & Kaur, K. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c01530 · Cited by 246
Triple-negative breast cancer: promising prognostic biomarkers currently in development
Sukumar, J., Gast, K., Quiroga, D., Lustberg, M., & Williams, N. (2021) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2021.1840984 · Cited by 239
Targeted inhibition of gut bacterial β-glucuronidase activity enhances anticancer drug efficacy
Bhatt, A. P., Pellock, S. J., Biernat, K. A., Walton, W. G., Wallace, B. D., Creekmore, B. C., Letertre, M. M., Swann, J. R., Wilson, I. D., Roques, J. R., et al. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1918095117 · Cited by 221
“Irinotecan formulations have been examined in mouse models of breast cancer (24), and human clinical trials for breast cancer have used SN38 combination therapies (25).”
BackgroundAsleh, K., Riaz, N., & Nielsen, T. O. (2022) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-022-02476-1 · Cited by 209
“Sacitizumab govitecanhziy received accelerated approval for use in heavily pretreated metastatic TNBC patients in April 2020 [153].”
BackgroundTriple Negative Breast Cancer: Updates on Classification and Treatment in 2021
Bou Zerdan, M., Ghorayeb, T., Saliba, F., Allam, S., Bou Zerdan, M., Yaghi, M., Bilani, N., Jaafar, R., & Nahleh, Z. (2022) · Cancers · doi:10.3390/cancers14051253 · Cited by 208
“It allows for targeted delivery of SN-38 to tumor cells, by bypassing the pharmacokinetic issues seen with Irinotecan [41,44,45] The drug was first approved by the United States Food and Drug Administration (FDA) in April 2020 after showing an Objective Response Rate (ORR) of 33%, a median progression free survival (P…”
BackgroundInfluentialMolecular Mechanisms, Biomarkers and Emerging Therapies for Chemotherapy Resistant TNBC
Ferrari, P., Scatena, C., Ghilli, M., Bargagna, I., Lorenzini, G., & Nicolini, A. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23031665 · Cited by 201
Mechanisms of Therapeutic Antitumor Monoclonal Antibodies
Tsao, L.-C., Force, J., & Hartman, Z. C. (2021) · Cancer Research · doi:10.1158/0008-5472.can-21-1109 · Cited by 198
“Recently, two other ADCs have been approved for solid cancers, enfortumab vedotin for urothelial carcinoma and sacituzumab govitecan for TNBC.”
BackgroundInfluentialWu, Q., Qian, W., Sun, X., & Jiang, S. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01362-9 · Cited by 200
A review of the clinical efficacy of FDA-approved antibody‒drug conjugates in human cancers
Liu, K., Li, M., Li, Y., Li, Y., Chen, Z., Tang, Y., Yang, M., Deng, G., & Liu, H. (2024) · Molecular Cancer · doi:10.1186/s12943-024-01963-7 · Cited by 196
“The most common AEs included nausea, neutropenia, diarrhea, fatigue, and anemia [89].”
BackgroundPrecision medicine for human cancers with Notch signaling dysregulation (Review)
Katoh, M., & Katoh, M. (2019) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2019.4418 · Cited by 191
“Trastuzumab-based Adcs with distinct linkers and payloads (trastuzumab deruxtecan and trastuzumab duocarmazine) (187,188); other Adcs targeting epidermal growth factor receptor (EGFR) (189), folate receptor-α (190), NEcTIN4 (191) and tumor-associated calcium signal transducer 2 (192); and cAR-Ts targeting”
BackgroundGu, W., Meng, F., Haag, R., & Zhong, Z. (2021) · Journal of Controlled Release · doi:10.1016/j.jconrel.2020.10.003 · Cited by 195
Antibody–Drug Conjugates: A Review of Approved Drugs and Their Clinical Level of Evidence
Gogia, P., Ashraf, H., Bhasin, S., & Xu, Y. (2023) · Cancers · doi:10.3390/cancers15153886 · Cited by 181
Recent advances of antibody drug conjugates for clinical applications
Zhao, P., Zhang, Y., Li, W., Jeanty, C., Xiang, G., & Dong, Y. (2020) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2020.04.012 · Cited by 176
Brucea javanica derived exosome-like nanovesicles deliver miRNAs for cancer therapy
Yan, G., Xiao, Q., Zhao, J., Chen, H., Xu, Y., Tan, M., & Peng, L. (2024) · Journal of Controlled Release · doi:10.1016/j.jconrel.2024.01.060 · Cited by 170
Emerging strategies for treating metastasis
Esposito, M., Ganesan, S., & Kang, Y. (2021) · Nature Cancer · doi:10.1038/s43018-021-00181-0 · Cited by 172
Triple-negative breast cancer: current perspective on the evolving therapeutic landscape
Mehanna, J., Haddad, F. G., Eid, R., Lambertini, M., & Kourie, H. R. (2019) · International Journal of Women's Health · doi:10.2147/ijwh.s178349 · Cited by 172
New and Emerging Targeted Therapies for Advanced Breast Cancer
Lau, K. H., Tan, A. M., & Shi, Y. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23042288 · Cited by 168
“Therefore, the anti-trop-2 antibody allows IMMU-132 to specifically deliver SN-38 to the breast cancer cells and the surrounding tumor via the cleavable linker [73].”
BackgroundGoldenberg, D. M., & Sharkey, R. M. (2019) · mAbs · doi:10.1080/19420862.2019.1632115 · Cited by 164
Self-citationMechanisms of Resistance to Antibody-Drug Conjugates
Khoury, R., Saleh, K., Khalife, N., Saleh, M., Chahine, C., Ibrahim, R., & Lecesne, A. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24119674 · Cited by 159
“It was the first ADC approved for triple-negative breast cancer (TNBC) based on the results of the IMMU-132-01 and ASCENT trials [26,47].”
ResultMechanisms of Resistance to Antibody–Drug Conjugates
Abelman, R. O., Wu, B., Spring, L. M., Ellisen, L. W., & Bardia, A. (2023) · Cancers · doi:10.3390/cancers15041278 · Cited by 177
“The next antibody–drug conjugate approved for use in breast cancer was sacituzumab govitecan (SG), composed of a monoclonal antibody targeting TROP-2 that is connected via a cleavable linker to SN-38, an irinotecan metabolite [14] (Figure 1).”
BackgroundSelf-citationTriptolide: reflections on two decades of research and prospects for the future
Tong, L., Zhao, Q., Datan, E., Lin, G.-Q., Minn, I., Pomper, M. G., Yu, B., Romo, D., He, Q., & Liu, J. O. (2020) · Natural Product Reports · doi:10.1039/d0np00054j · Cited by 160
Wahby, S., Fashoyin‐Aje, L. A., Osgood, C. L., Cheng, J., Fiero, M. H., Zhang, L., Tang, S. W., Hamed, S. S., Song, P., Charlab, R., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-3119 · Cited by 165
Kalinsky, K. M., Diamond, J. R., Vahdat, L. T., Tolaney, S. M., Juric, D., O’Shaughnessy, J., Moroose, R. L., Mayer, I. A., Abramson, V. G., Goldenberg, D. M., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.09.004 · Cited by 163
Self-citationTargeted therapy for breast cancer: An overview of drug classes and outcomes
Jacobs, A. T., Castaneda-Cruz, D. M., Rose, M. M., & Connelly, L. (2022) · Biochemical Pharmacology · doi:10.1016/j.bcp.2022.115209 · Cited by 173
Progress and Prospect of Immunotherapy for Triple-Negative Breast Cancer
Luo, C., Wang, P., He, S., Zhu, J., Shi, Y., & Wang, J. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.919072 · Cited by 166
“In a recent clinical trial, it has been reported that sacituzumab govitecan-hziy was associated with durable objective responses in patients with heavily pretreated metastatic TNBC (32).”
BackgroundTrop2 is a driver of metastatic prostate cancer with neuroendocrine phenotype via PARP1
Hsu, E.-C., Rice, M. A., Bermudez, A., Marques, F. J. G., Aslan, M., Liu, S., Ghoochani, A., Zhang, C. A., Chen, Y.-S., Zlitni, A., et al. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1905384117 · Cited by 146
Coussy, F., Botty, R. E., Château‐Joubert, S., Dahmani, A., Montaudon, É., Leboucher, S., Morisset, L., Painsec, P., Sourd, L., Huguet, L., et al. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.aax2625 · Cited by 159
Antibody-drug conjugates targeting TROP-2: Clinical development in metastatic breast cancer
Shastry, M., Jacob, S., Rugo, H. S., & Hamilton, E. (2022) · The Breast · doi:10.1016/j.breast.2022.10.007 · Cited by 143
“This led to IMMU-132-01 (NCT01631552), a phase I/II multi-center basket trial which enrolled 108 patients with TNBC and a least 2 prior lines of chemo to receive 10 mg/kg of SG on Day 1 and 8 of a 21-day cycle [33].”
BackgroundMethodSelf-citationNovel antibody–drug conjugates for triple negative breast cancer
Nagayama, A., Vidula, N., Ellisen, L. W., & Bardia, A. (2020) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835920915980 · Cited by 157
Self-citationOverview of recent advances in metastatic triple negative breast cancer
O'Reilly, D., AlSendi, M., & Kelly, C. M. (2021) · World Journal of Clinical Oncology · doi:10.5306/wjco.v12.i3.164 · Cited by 159
Potential of antibody–drug conjugates (ADCs) for cancer therapy
Marei, H. E. S., Cenciarelli, C., & Hasan, A. (2022) · Cancer Cell International · doi:10.1186/s12935-022-02679-8 · Cited by 155
Trop2: Jack of All Trades, Master of None
Lénart, S., Lenárt, P., Šmarda, J., Remšík, J., Souček, K., & Beneš, P. (2020) · Cancers · doi:10.3390/cancers12113328 · Cited by 154
Development of therapeutic antibodies for the treatment of diseases
Wang, Z., Wang, G., Lu, H., Li, H., Tang, M., & Tong, A. (2022) · Molecular Biomedicine · doi:10.1186/s43556-022-00100-4 · Cited by 157
Yang, R., Li, Y., Wang, H., Qin, T., Yin, X., & Ma, X. (2022) · Molecular Biomedicine · doi:10.1186/s43556-022-00071-6 · Cited by 155
Hammood, M., Craig, A. W., & Leyton, J. V. (2021) · Pharmaceuticals · doi:10.3390/ph14070674 · Cited by 148
Rugo, H. S., Bardia, A., Tolaney, S. M., Arteaga, C. L., Cortés, J., Sohn, J., Marmé, F., Hong, Q., Delaney, R., Hafeez, A., et al. (2020) · Future Oncology · doi:10.2217/fon-2020-0163 · Cited by 137
Self-citationAdvances in Trop2-targeted therapy: Novel agents and opportunities beyond breast cancer
Liu, X., Deng, J., Yuan, Y., Chen, W., Sun, W., Wang, Y., Huang, H., Liang, B., Ming, T., Wen, J., et al. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2022.108296 · Cited by 154
Lu, G., Nishio, N., van den Berg, N. S., Martin, B. A., Fakurnejad, S., van Keulen, S., Colevas, A. D., Thurber, G. M., & Rosenthal, E. L. (2020) · Nature Communications · doi:10.1038/s41467-020-19498-y · Cited by 136
Sacituzumab govitecan, a novel, third-generation, antibody-drug conjugate (ADC) for cancer therapy
Goldenberg, D. M., & Sharkey, R. M. (2020) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2020.1757067 · Cited by 141
“As mentioned, the results were very favorable, especially considering that the 108 ECOG 0–1 patients with TNBC had received a median of three prior therapies (ranging from 2 to 10), and 98% and 86% received prior taxanes and anthracyclines, respectively [107].”
BackgroundResultSelf-citationLi, M., Guo, T., Lin, J., Huang, X., Ke, Q., Wu, Y., Fang, C., & Hu, C. (2021) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2021.114689 · Cited by 126
An Overview of Antibody Conjugated Polymeric Nanoparticles for Breast Cancer Therapy
Juan, A., Cimas, F. J., Bravo, I., Pandiella, A., Ocaña, A., & Alonso‐Moreno, C. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics12090802 · Cited by 128
“In this regard, ADCs can be based on antibodies that lack tumor specificity, like the recently approved ADC, sacituzumab-govitecan, against the trophoblast cell surface antigen 2 (Trop-2) [144,145].”
BackgroundBiomarkers in Triple-Negative Breast Cancer: State-of-the-Art and Future Perspectives
Cocco, S., Piezzo, M., Calabrese, A., Cianniello, D., Caputo, R., Lauro, V. D., Fusco, G., Gioia, G. D., Licenziato, M., & Laurentiis, M. D. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21134579 · Cited by 137
Antibody Conjugates-Recent Advances and Future Innovations
Leung, D., Wurst, J., Liu, T., Martinez, R., Datta‐Mannan, A., & Feng, Y. (2020) · Antibodies · doi:10.3390/antib9010002 · Cited by 125
“Nevertheless, this ADC demonstrated significant antitumor effects in mice bearing human pancreatic or gastric cancer xenografts [32] and is showing promise in clinical trials [33,34].”
BackgroundRugo, H. S., Tolaney, S. M., Loirat, D., Punie, K., Bardia, A., Hurvitz, S. A., O’Shaughnessy, J., Cortés, J., Dieras, V. C., Carey, L., et al. (2022) · npj Breast Cancer · doi:10.1038/s41523-022-00467-1 · Cited by 124
“Nausea 123 (59) 6 (3) 1 (<1) 24 (49) 0 0 48 (27) 0 0 11 (23) 1 (2) 0”
Self-citationManjunath, M., & Choudhary, B. (2021) · Oncology Letters · doi:10.3892/ol.2021.12773 · Cited by 127
Shah, P. D., Huang, A. C. C., Xu, X., Orlowski, R. J., Amaravadi, R. K., Schuchter, L. M., Zhang, P. J., Tchou, J. C., Matlawski, T., Cervini, A., et al. (2023) · Cancer Research Communications · doi:10.1158/2767-9764.crc-22-0486 · Cited by 120
“inhibitors (6, 7) and antibody–drug conjugates (8) more recently approved but effective in a minority of patients.”
BackgroundEmerging CAR-T Cell Therapy for the Treatment of Triple-Negative Breast Cancer
Dees, S., Ganesan, R., Singh, S., & Grewal, I. S. (2020) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-20-0385 · Cited by 118
“The safety of TROP2 targeting has been demonstrated in the clinic with minimal toxicity observed in normal tissues, and has thus emerged as an attractive therapeutic target in TNBC (113, 114).”
BackgroundDum, D., Taherpour, N., Menz, A., Höflmayer, D., Völkel, C., Hinsch, A., Gorbokon, N., Lennartz, M., Hube‐Magg, C., Fraune, C., et al. (2022) · Pathobiology · doi:10.1159/000522206 · Cited by 121
Antibody–drug conjugates in cancer therapy: current landscape, challenges, and future directions
Chen, B., Zheng, X., Wu, J., Chen, G., Yu, J. Q., Xu, Y. X., Wu, W. K. K., Tse, G. M.-K., To, K. F., & Kang, W. (2025) · Molecular Cancer · doi:10.1186/s12943-025-02489-2 · Cited by 131
Antibody-Drug Conjugates for the Treatment of HER2-Positive Breast Cancer
Najjar, M. K., Manore, S. G., Regua, A. T., & Lo, H. (2022) · Genes · doi:10.3390/genes13112065 · Cited by 123
“HER2 is overexpressed in 15–20% of breast cancer while TROP2 is overexpressed in more than 85% of triple negative breast cancer (TNBC) [117,118].”
BackgroundToxicity profile of antibody-drug conjugates in breast cancer: practical considerations
D’Arienzo, A., Verrazzo, A., Pagliuca, M., Napolitano, F., Parola, S., Viggiani, M., Caputo, R., Puglisi, F., Giuliano, M., Mastro, L. D., et al. (2023) · EClinicalMedicine · doi:10.1016/j.eclinm.2023.102113 · Cited by 113
Cutting-edge approaches for targeted drug delivery in breast cancer: beyond conventional therapies
Chaudhari, R. H., Patel, V., & Kumar, A. (2024) · Nanoscale Advances · doi:10.1039/d4na00086b · Cited by 124
“77 Liang and colleagues 78 utilized cationic liposomes decorated with peptide-p37 (CDO14) to administer siRNA in breast cancer cells overexpressing heat-shock-protein-gp96.”
Subhan, M. A., Parveen, F., Shah, H., Yalamarty, S. S. K., Ataide, J. A., & Torchilin, V. P. (2023) · Cancers · doi:10.3390/cancers15082204 · Cited by 118
“During the IMMU-132-01, a phase I/II trial, sacituzumab govitecan was associated with durable objective responses in refractory metastatic TNBC, with myelotoxicity as the main adverse effect observed [125].”
BackgroundTriple Negative Breast Cancer: A Mountain Yet to Be Scaled Despite the Triumphs
Wu, Q., Siddharth, S., & Sharma, D. (2021) · Cancers · doi:10.3390/cancers13153697 · Cited by 122
Spring, L. M., Nakajima, E., Hutchinson, J. A., Viscosi, E., Blouin, G. C., Weekes, C. D., Rugo, H. S., Moy, B., & Bardia, A. (2021) · The Oncologist · doi:10.1002/onco.13878 · Cited by 117
“The most common adverse events (AEs) in the 108 patients with mTNBC who received sacituzumab govitecan in the IMMU-132-01 trial were nausea (67%), diarrhea (62%), fatigue (55%), neutropenia (64%), and anemia (50%) [26].”
BackgroundInfluentialSelf-citationTargeting Engineered Nanoparticles for Breast Cancer Therapy
Ganesan, K., Wang, Y., Gao, F., Liu, Q., Zhang, C., Li, P., Zhang, J., & Chen, J. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13111829 · Cited by 108
Maitland, M. L., Sachdev, J. C., Sharma, M. R., Moreno, V., Boni, V., Kummar, S., Stringer-Reasor, E. M., Lakhani, N. J., Moreau, A. R., Xuan, D., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-3757 · Cited by 102
Programming tissue-sensing T cells that deliver therapies to the brain
Simic, M., Watchmaker, P. B., Gupta, S., Wang, Y., Sagan, S. A., Duecker, J., Shepherd, C., Diebold, D., Pineo-Cavanaugh, P. L., Haegelin, J., et al. (2024) · Science · doi:10.1126/science.adl4237 · Cited by 105
Can EGFR be a therapeutic target in breast cancer?
Li, X., Zhao, L., Chen, C., Nie, J., & Jiao, B. (2022) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2022.188789 · Cited by 110
Trop-2 as a Therapeutic Target in Breast Cancer
Sakach, E. A., Sacks, R. L., & Kalinsky, K. M. (2022) · Cancers · doi:10.3390/cancers14235936 · Cited by 107
“The efficacy of sacituzumab govitecan in TNBC was further evidenced in the multicenter, phase I/II, single-arm trial IMMU-132-01 that evaluated patients with advanced solid tumors, including 108 patients with metastatic TNBC who had received at least 2 therapies for metastatic disease [47].”
MethodSelf-citationChinese Society of Clinical Oncology (CSCO) Breast Cancer guidelines 2024
Li, J., Hao, C., Wang, K., Zhang, J., Chen, J., Liu, Y., Nie, J., Yan, M., Liu, Q., Geng, C., et al. (2024) · Translational Breast Cancer Research · doi:10.21037/tbcr-24-31 · Cited by 116
“In the ASCENT study, patients with advanced TNBC who had received prior second-or later-line chemotherapy were randomized to receive sacituzumab govitecan or single-agent chemotherapy (including capecitabine, eribulin, vinorelbine, or gemcitabine, upon the investigator’s choice), respectively (40).”
Trop2-targeted therapies in solid tumors: advances and future directions
Liu, X., Ma, L., Li, J., Sun, L., Yang, Y., Liu, T., Xing, D., Yan, S., & Zhang, M. (2024) · Theranostics · doi:10.7150/thno.98178 · Cited by 102
Targeting Breast Cancer: An Overlook on Current Strategies
Iacopetta, D., Ceramella, J., Baldino, N., Sinicropi, M., & Catalano, A. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24043643 · Cited by 88
“Trop-2 is present in BC cells, therefore, the anti-Trop-2 antibody allows IMMU-13 to spec fically d liver SN-38 to the BC cells and the surrounding tumor via the clea ble linker [246].”
BackgroundEsapa, B., Jiang, J., Cheung, A., Chenoweth, A. M., Thurston, D. E., & Karagiannis, S. N. (2023) · Cancers · doi:10.3390/cancers15061845 · Cited by 97
Advances in Antibody–Drug Conjugate Design: Current Clinical Landscape and Future Innovations
Gauzy, L., Sassoon, I., & Brun, M. (2020) · SLAS DISCOVERY · doi:10.1177/2472555220912955 · Cited by 92
Corti, C., Venetis, K., Sajjadi, E., Zattoni, L., Curigliano, G., & Fusco, N. (2022) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2022.2054326 · Cited by 96
Spring, L. M., Tolaney, S. M., Fell, G. G., Bossuyt, V., Abelman, R. O., Wu, B., Maheswaran, S., Trippa, L., Comander, A. H., Mulvey, T. M., et al. (2023) · Annals of Oncology · doi:10.1016/j.annonc.2023.11.018 · Cited by 99
Self-citation
Metadata
- Authors
- Bardia, A., Mayer, I. A., Vahdat, L. T., Tolaney, S. M., Isakoff, S. J., Diamond, J. R., O’Shaughnessy, J., Moroose, R. L., Santin, A. D., Abramson, V. G., Shah, N. C., Rugo, H. S., Goldenberg, D. M., Sweidan, A. M., Iannone, R., Washkowitz, S., Sharkey, R. M., Wegener, W. A., & Kalinsky, K.
- Affiliations
- Harvard University (US)
- Vanderbilt University (US)
- Cornell University (US)
- Orlando Health (US)
- University of California, San Francisco (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2019-02-21
- Volume
- 380
- Issue
- 8
- Pages
- 741-751
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2917403028
- Cited by
- 874
- References
- 37
- Citations by year
- 2026: 76 · 2025: 103 · 2024: 111 · 2023: 125 · 2022: 167 · 2021: 167 · 2020: 91 · 2019: 32
- FWCI
- 36.24
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Immunomedics Inc
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
- Health Sciences › Medicine › Oncology › Advanced Breast Cancer Therapies
- Health Sciences › Medicine › Oncology › Cancer Treatment and Pharmacology
- Keywords
- sacituzumab govitecan, antibody-drug conjugates, metastatic triple-negative breast cancer, TROP2, SN-38, refractory disease, objective response rate, duration of response, progression-free survival, overall survival, safety, febrile neutropenia, anemia, neutropenia
- MeSH terms
- Irinotecan, Progression-Free Survival, Adult, Aged, Aged, 80 and over, Anemia, Antigens, Neoplasm, Antineoplastic Agents, Camptothecin, Diarrhea, Dose-Response Relationship, Drug, Female, Humans, Infusions, Intravenous, Male, Middle Aged, Neutropenia, Cell Adhesion Molecules, Survival Rate, Immunoconjugates, Antibodies, Monoclonal, Humanized, Triple Negative Breast Neoplasms
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.